The potential role of cyclooxygenase-2 inhibitors and 5α-reductase inhibitors in the prevention of urologic conditions

Urologic Clinics of North America

Volumn 31, Issue 2, 2004, Pages 213-218

  Hernandez, Javier ^a   Basler, Joseph W ^a   Thompson, Ian M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; FINASTERIDE; GONADORELIN AGONIST; KETOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; STEROID 5ALPHA REDUCTASE INHIBITOR; SULINDAC;

ADENOMATOUS POLYP; AFRICAN AMERICAN; AGE; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; CRYPTORCHISM; DRUG MECHANISM; ETHNOLOGY; FAMILY HISTORY; HUMAN; KIDNEY CARCINOMA; NONHUMAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PUBLIC HEALTH; REPRODUCTIVE TOXICITY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SMOKING; TESTIS CANCER; UROGENITAL TRACT CANCER; UROLOGY; VON HIPPEL LINDAU DISEASE;

ADULT; AGE DISTRIBUTION; AGED; CHOLESTENONE 5 ALPHA-REDUCTASE; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; URINARY BLADDER NEOPLASMS; UROLOGIC DISEASES;

EID: 2342627337     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2004.01.009     Document Type: Review

References (49)

1. Clark L.T. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J. 145:(3):2003;387-396
2. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol. 17:(5):2002;552-558
3. Ford L.G., Minasian L.M., McCaskill-Stevens W., et al. Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA Cancer J Clin. 53:2003;82-101
4. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 349:2003;215-224
5. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowerl Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388
6. Klein E.A., Lippman S.M., Thompson I.M., Goodman P.J., et al. The selenium and vitamin E cancer prevention trial. World J Urol. 21:(1):2003;21-27
7. Smith W.L., De Witt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 69:2000;145-182
8. Koki A.T., Leahy K.M., Masferrer J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs. 8:1999;1623-1638
9. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc Δ 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809
10. Steinbach G., Lynch P., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:2000;1946-1952
11. Subongkot S., Frame D., Leslie W., Drajer D. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy. 23:(1):2003;9-28
12. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:(2):1993;156-160
13. Hsu A.L., Ching T.T., Wang D.S., Song X., et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 275:(15):2000;11397- 11403
14. Liu X.H., Yau S., Kirshenbaum A., Levine A.C. NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245-4249
15. Liu X.H., Kirschenbaum A., Yao S., Lee R., et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 164:(3 Pt 1):2000;820-825
16. Kamijo T., Sato T., Nagatomi Y., Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 8:(7):2001;S35-S39
17. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 42:2000;73-78
18. Roberts R.O., Jacobson D.J., Girman C.J., Rhodes T., et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc. 77:2002;219
19. Nelson J.E., Harris R.E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep. 7:(1):2000;169-170
20. Habel L.A., Zhao W., Stanford J.L. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control. 13:(5):2002;427-434
21. Irani J., Ravery V., Pariente J.L., Chartier-Kastler E., et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol. 168:(5):2002;1985-1988
22. Pruthi R.S., Derksen J.E., Gaston K. Re: effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. [comment] J Urol. 169:(6):2003;2304
23. Derksen J.E., Pruthi R.S. COX-2 inhibitors in PSA recurrent prostate cancer: a pilot study. [abstract 1199] J Urol. 167:(Suppl):2002;304
24. Jemal A., Murray T., Samuels A., Ghafoor A., et al. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26
25. Cohen S.M., Zenser T.V., Murasaki G., Fukushima S., et al. Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res. 41:(9 Pt 1):1981;3355-3359
26. Rao K.V., Detrisac C.J., Steele V.E., Hawk E.T., et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 17:(7):1996;1435-1438
27. Okajima E., Denda A., Ozono S., Takahama M., et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4- hydroxybutyl)nitrosamine. Cancer Res. 58:(14):1998;3028-3031
28. Mizutani Y., Kamoi K., Ukimura O., Kawauchi A., et al. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol. 168:(6):2002;2650-2654
29. Mohammed S.I., Bennett P.F., Craig B.A., Glickman N.W., et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 62:(2):2002;356-358
30. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:(20):2000;5599-5602
31. Mohammed S.I., Knapp D.W., Bostwick D.G., Foster R.S., et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59:(22):1999;5647-5650
32. El-Sheikh S.S., Madaan S., Alhasso A., Abel P., et al. Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer. BJU Int. 88:(9):2001;921-927
33. Shirahama T., Arima J., Akiba S., Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 92:(1):2001;188-193
34. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C., et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 82:(7):2000;1364-1369
35. Khan K.N., Stanfield K.M., Trajkovic D., Knapp D.W. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol. 38:(1):2001;116-119
36. Okamoto T., Hara A., Hino O. Down-regulation of cyclooxygenase-2 expression but up-regulation of cyclooxygenase-1 in renal carcinomas of the Eker (TSC2 gene mutant) rat model. Cancer Sci. 94:(1):2003;22-25
37. Castilla E., Liou L., Abrahams N., et al. Expression of cyclooxygenase-2 (Cox-2) in renal cell carcinoma (RCC): immunohistochemical study using a high-throughput tissue microarray (TMA) and oligo microarray evaluation. [abstract 502] J Urol. 167:(Suppl):2002;126
38. Chen W., Shinohara N., Koyanagi T. Significance of cyclooxygenase-2 expression in human renal cell carcinoma cell lines. J Urol. (Suppl):2002;167
39. Imperato-McGinley J.L., Guerrero L., Gautier T., et al. Steroid 5 alpha-reductase deficiency in men: an inherited form of male pseudohermaphroditism. Science. 186:1974;1213
40. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5-alpha-reductase deficiency. J Clin Endocrinol Metab. 75:1992;1022
41. Gormley G.J., Stoner E., Rittmaster R.S., et al. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 70:(4):1990;1136-1141
42. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563
43. McConnell J.D., for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol. 167:2002;1042
44. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 170:2003;530
45. Ross R.K., Bernstein L., Lobo R.A., et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 339:1992;887
46. Tsukamoto S., Akaza H., Onozawa M., et al. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer. 82:(3):1998;531-537
47. Cote R.J., Skinner E.C., Salem C.E., et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer. 78:1998;413-418
48. Algaba F., Epstein J.I., Aldape H.C., et al. Assessment of prostate carcinoma in core needle biopsy: definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 78:1996;376-381
49. Thompson I.M., Kouril M., Klein E.A., et al. The Prostate Cancer Prevention Trial: current status and lessons learned. Urology. 57:(4 Suppl. 1):2001;230-234